Opioid Use Disorder Market - Global Market Share, Trends, Analysis and Forecast 2022 – 2032

The global opioid use disorder market size was estimated to be US$ 2.52 billion in 2020 and is expected to reach US$ 6.2 billion by 2031 at a CAGR of 8.5%.

Everyone these days experiences a wide scope of ongoing and extreme medical issue, for example, pain emerging from wounds or disease. They regularly bring about persistent agony and in such cases, patients are given painkillers, particularly opioids. While they help in bringing down torment, they can cause habit among patients. The sudden stopping or higher reliance on these drugs prompts withdrawal side effects. This further expands the odds of deadly results, like deaths.

Opioid Use Disorder (OUD) is an ongoing condition related with urgent, delayed, and rehashed consumption of opioids. There are two kinds of patients experiencing OUD, patients who are dependent on non-clinical opioids and patients dependent on clinical opioids. A solitary factor can't be represented OUD, yet a mix of natural and hereditary factors impact the patient. Suboxone is the most endorsed drug in the OUD market, because of its amazing clinical profile. High viability in overseeing addiction, with low potential for abuse and somewhat gentle unfriendly impacts and its good model inclusion are factors that can be ascribed to the high reception of this medication.

Buprenorphine-Sublocade is expected to be the quickest developing industry as it coordinates the limitations of existing treatment by supplanting day by day oral meds with an injectable, in this way, making redirection and abuse troublesome along with working on personal satisfaction. North America is the biggest market because of the pandemic of opioids in the U.S. also, Canada, and the presentation of strategies by the local governments to control the emergency situation. The U.S. government in January 2018 dispatched an awareness effort to oppose opioid addiction.

The clinic drug stores segment is expected to represent a higher share in the worldwide market because of the reliance of the patient populace on these settings for the organization of parenteral OUD drugs, for example, buprenorphine. The retail drug stores and stores segment is set to be the second-biggest segment during the approaching a long time because of the reliance of the patient populace on these areas for topping off their solutions.

North America was the biggest income producing province in 2019 and is relied upon to show a similar pattern during the forecast period. The opioid plague in the U.S. furthermore, Canada is probably the greatest factor adding to the biggest portion of the overall industry of North America. Governments are acquainting a few strategies with control the emergency. For example, in January 2018, the U.S. government dispatched an awareness promoting effort to battle opioid habit.

Global Opioid Use Disorder Market Value Share Analysis, by Geography (2021)

The report titled “Global Opioid Use Disorder Market - Global Market Share, Trends, Analysis and Forecasts, 2022-2032”, wherein 2020 is historic period, 2021 is the base year, and 2022 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the Global Opioid Use Disorder Market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.

The global Opioid Use Disorder market is segmented as drug class, route of administration, distribution channel, and region. Based on drug class, the Opioid Use Disorder market is segmented into Buprenorphine, Methadone, Naltrexone, Others. Based on route of administration, the Opioid Use Disorder market is segmented into Oral, Parenteral, other. Based on distribution channel, the Opioid Use Disorder market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores, Online Pharmacies, others.

Based on geography, the Global Opioid Use Disorder Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Italy, France, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, UAE, South Africa and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.

The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on Global Opioid Use Disorder Market. Further, market share of prominent companies in the Global Opioid Use Disorder Market would also be estimated. 

The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the Opioid Use Disorder companies. The Global Opioid Use Disorder Market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the Opioid Use Disorder business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the Global Opioid Use Disorder Market.

The key players of the Global Opioid Use Disorder Market are Indivior PLC, Titan Pharmaceuticals, Inc., BioDelivery Sciences International, Inc., Alkermes, Inc., Omeros Corporation, Camurus, Hikma Pharmaceuticals PLC, and others.

Global Opioid Use Disorder Market Key Segments:

Based on drug class

• Buprenorphine
• Methadone
• Naltrexone
• Others

Based on route of administration

• Oral
• Parenteral
• Others

Based on distribution channel

• Hospital Pharmacies
• Retail Pharmacies & Stores
• Online Pharmacies
• Others

By Region

• North America
  • United States
  • Canada
  • Rest of North America
• Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East & Africa
  •  UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa
• South America
  • Brazil
  • Rest of South America